The infertility ‘blame game’: When did women become the

Infertility represents one of Africa's most significant yet underexplored public health challenges, affecting an estimated 30-40% of couples across sub-Saharan Africa according to WHO data. Yet as healthcare systems grapple with this reality, a troubling cultural pattern has emerged: women bear the overwhelming burden of blame, stigma, and medical intervention, despite male factor infertility accounting for approximately 40-50% of cases across the continent.

This gender-skewed narrative carries profound implications for European investors eyeing Africa's healthcare expansion. The fertility treatment market in Africa is projected to reach $2.1 billion by 2030, driven by rising middle-class incomes, urbanization, and increasing access to assisted reproductive technologies (ART). However, the current landscape remains fragmented, undersupplied, and distorted by cultural assumptions that primarily target female patients while marginalizing male diagnosis and treatment.

The reality on the ground reflects this imbalance starkly. In many African healthcare settings, when a couple presents with infertility, women immediately undergo invasive diagnostic procedures—hysterosalpingography, laparoscopy, and hormonal assessments—often without corresponding male partner evaluation. Men, by contrast, frequently avoid fertility clinics entirely due to social stigma linking infertility with masculinity or virility. This creates a perverse market dynamic where fertility service providers have optimized their offerings around female clients, missing half their potential patient base and, critically, missing cases where male factor infertility is the primary issue.

For European healthcare investors and medical technology companies, this presents both opportunity and complexity. The immediate opportunity lies in establishing comprehensive, couple-centered fertility clinics that break from traditional models. Modern diagnostic protocols—including semen analysis, genetic screening, and reproductive immunology for both partners—remain largely unavailable outside major metropolitan centers. European firms with expertise in point-of-care diagnostics, telemedicine consultation, and standardized fertility protocols can capture significant market share by positioning themselves as evidence-based alternatives to fragmented, gender-biased local providers.

However, success requires navigating entrenched cultural attitudes. Healthcare providers operating in East Africa, West Africa, and Southern Africa must invest in community education and stakeholder engagement that reframes infertility as a couple's condition requiring joint diagnosis and treatment. This cultural repositioning is neither quick nor inexpensive, but it's essential for sustainable business models.

The regulatory environment further complicates the picture. Kenya, Nigeria, and South Africa have begun developing ART regulatory frameworks, but inconsistency across borders creates operational challenges for multinational providers. Additionally, religious and traditional belief systems in many markets create resistance to certain fertility treatments, particularly in-vitro fertilization (IVF), requiring careful market segmentation and localized messaging.

European investors should also recognize that gender bias in fertility care reflects broader healthcare system weaknesses—inadequate male health screening, poor diagnostic infrastructure, and limited specialist availability. Companies that address these root causes through training programs, equipment investment, and digital solutions will build defensible competitive advantages.

The market is nascent but growing. Early-moving European firms can establish category leadership while simultaneously advancing gender-equitable healthcare delivery—a combination that drives both financial returns and social impact.